Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Protalix Biotherapeutics (PLX) AMEX

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 30,980
  • Shares Outstanding, K 99,810
  • Annual Sales, $ 4,360 K
  • Annual Income, $ 58,040 K
  • 36-Month Beta 0.55
  • Price/Sales 7.10
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.27 +18.52%
on 12/05/16
0.65 -50.77%
on 11/29/16
-0.11 (-25.58%)
since 11/04/16
3-Month
0.27 +18.52%
on 12/05/16
0.65 -50.77%
on 11/29/16
-0.28 (-46.67%)
since 09/02/16
52-Week
0.27 +18.52%
on 12/05/16
1.05 -69.52%
on 12/18/15
-0.68 (-68.00%)
since 12/04/15

Most Recent Stories

More News
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 14.3%

Protalix BioTherapeutics, Inc. (PLX) moved big last session, as its shares jumped a little over 14% on the day.

Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enrolled in its phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis. OPRX-106...

Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results

Patient Enrollment Ongoing for Phase III Fabry Clinical Trial with approximately 10 Patients Currently in Evaluation and Screening Stages

Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been dosed in its global phase III clinical trial of PRX-102 for the treatment of Fabry disease. There...

Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today an oral presentation highlighting the results of the phase I/II clinical trial of PRX-102 for the treatment of Fabry disease will...

Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant,...

Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results

Patient Screening Underway for Fabry Phase III Clinical Trial

BUYINS.NET: CSJ, DGL, PLX, DBP, EWD, CISG Are Seasonally Ripe To Go Up In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of iShares Barclays 1-3 Year Credit Bond Fund (NYSE:CSJ), PowerShares DB Gold Fund (NYSE:DGL), PROTALIX BIOTHERAPEUTICS INC (NYSE:PLX),...

Protalix Meets FDA, To Start Phase III Fabry Disease Study

Protalix (PLX) conducted an end-of-phase II meeting with the FDA to discuss the proposed BLA plan for PRX-102 for the treatment of Fabry disease.

Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA

Clear Path for Biologics License Application (BLA) Submission

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Support & Resistance

2nd Resistance Point 0.38
1st Resistance Point 0.35
Last Price 0.32
1st Support Level 0.28
2nd Support Level 0.24

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.